Log in

Company updateEconomic Times

Biocon gets USFDA nod for breast cancer biosimilar Pebrilzo

Positive+384 sources

GreyOak summary

Biocon Ltd received USFDA approval for Pebrilzo, a biosimilar to Perjeta for HER2-positive breast cancer. This marks the fifth oncology biosimilar therapy approved in the US for the company.

What it affects

  • BioconBIOCONPositive +38

    Received USFDA nod for breast cancer biosimilar Pebrilzo.Rolling sentiment Positive +21

Source

Read the original at Economic Times

More Biocon news

No other recent stories about Biocon.

All Biocon news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy